GPC2 CAR T Cells for Neuroblastoma and Retinoblastoma
This study is testing a new treatment called GPC2 CAR T cells for children with advanced neuroblastoma or metastatic retinoblastoma that has come back or not responded to other treatments. GPC2 CAR T cells are your own immune cells that have been specially trained to find and fight cancer cells that have a specific marker called GPC2. This is the first time this treatment is being given to people, and the main goals are to find the safest dose and to track any side effects over 5 years. The study aims to enroll 45 participants. This treatment is for patients aged 1 year or older with high-risk neuroblastoma or metastatic retinoblastoma.
- Study design
- This is a first-in-human dose escalation trial to determine the safety of GPC2 CAR T cells. It plans to enroll 45 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 5 years to track the maximum tolerated dose and frequency of adverse events.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Lisa Wray, MD · PRINCIPAL_INVESTIGATOR · Children's Hospital of Philadelphia
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Determine the Maximum Tolerated Dose of GPC2 CAR T cells5 years
The Maximum Tolerated Dose of GPC2 CAR T cells will be determined by measuring the incidence of dose limiting toxicities following administration of the product.
- Frequency of Adverse Events Following GPC2 CAR T cell administration5 years
Assess the frequency and severity of treatment related adverse events following administration of GPC2 CAR T cells.